Metropolis Q1FY27: Revenue up 17%, EBITDA up 27%, PAT up 26%

Pat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

METROPOLIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.2%Reaction day

₹589.90

prior close

₹590.00

announcement price

After-mkt

timing

Nifty Microcap 250market+1.3%-3.5% vs market

Healthcare Service Provider peers, median of 26sector-0.1%-2.1% vs sector

On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250 and 2.1 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.4

10m

-2.2

15m

-2.4

30m

-2.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.2+1.3-3.5-0.1-2.1

Next day

-5.4+1.6-7.1-2.2-3.2

-4.5+1.7-6.2-1.7-2.8

-2.9+1.6-4.5-0.9-2.0

-4.1+1.5-5.5-0.2-3.9

-6.4+1.8-8.2-0.1-6.3

-8.1+2.1-10.1-2.1-5.9

15d

-3.3+3.2-6.5-1.6-1.7

-1.8+3.7-5.5+0.2-2.0

-5.2+1.1-6.4-3.4-1.8

—————

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Metropolis Healthcare reported Q1FY27 consolidated revenue of ₹450.2 Cr, up 16.6% YoY. EBITDA grew 27.1% to ₹113.2 Cr with margin expanding 210 bps to 25.2%. PAT rose 25.8% to ₹56.9 Cr, with PAT margin at 12.6% (up 90 bps). Patient volume grew 10% and test volume 11%. B2C revenue up 18%, B2B up 15%. TruHealth grew 22%, Specialty 17%. Tier III cities were fastest at around 25% growth.

Likely market impact

Strong quarter with double-digit revenue, EBITDA and PAT growth plus margin expansion. Positive for investor sentiment.